- Home
- PEGA vs LEGN Comparison
PEGA vs LEGN Comparison
Compare PEGA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEGA | LEGN |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 5.9B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PEGA | LEGN |
|---|---|---|
| Price | $59.55 | $22.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $66.69 | ★ $69.67 |
| AVG Volume (30 Days) | 1.1M | ★ 2.6M |
| Earning Date | 10-21-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 116.89 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $1,732,325,000.00 | $909,045,000.00 |
| Revenue This Year | $18.29 | $68.83 |
| Revenue Next Year | $6.66 | $51.27 |
| P/E Ratio | $40.77 | ★ N/A |
| Revenue Growth | 17.00 | ★ 74.75 |
| 52 Week Low | $29.84 | $22.28 |
| 52 Week High | $68.10 | $45.30 |
Technical Indicators
Market Signals| Indicator | PEGA | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 21.96 |
| Support Level | $59.76 | $26.43 |
| Resistance Level | $62.46 | $28.97 |
| Average True Range (ATR) | 1.71 | 1.57 |
| MACD | 0.74 | -0.43 |
| Stochastic Oscillator | 66.63 | 0.91 |
Price Performance
Historical ComparisonAbout PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.